Table 2.
Overview of the lab findings of the included studies.
| Author | Lab Findings | |||
|---|---|---|---|---|
| Dreher, 2020 | All patients (N = 50) 6.7 (4.9–9.6) | Non-ARDS patients (N = 26) | ARDS patents (N = 24) | |
| WBC | 94 (28–173) | 5.8 (4.1–7) | 9.2 (6.3–11.6) | |
| C-reactive protein (mg/L) | 122 (68–333) | 37 (15–113) | 110 (7–264) | |
| Interleukin-6 (pg/mL) | 10 (0–60) | 119 (47–338) | ||
| Chen, 2020 | All patients (N = 21) | Moderate patients (N = 10) | Severe patents (N = 11) | |
| WBC | 5.7 (4.6–8.3) | 4.5 (3.9–5.5) | 8.3 (6.2–10.4) | |
| C-reactive protein (mg/L) | 108.4(28–139.5) | 22 (14.7–119.4) | 139.4 (86.9–165.1) | |
| Interleukin-6 (pg/mL) | 26.6 (7.5−43.4) | 15.3 (6.2−29.5) | 41.5 (24.8−114.2) | |
| Hou, 2020 | Odd ratio for severe COVID-19 | OR (97·5% CI = 2·5%) | P-value | |
| IL-1β | 1·0379 | 0·9739 1·1062 | 0·2515 | |
| IL-2R | 0·9993 | 0·9983 1·0004 | 0·2078 | |
| IL-6 | 1·0000 | 0·9903 1·0097 | 0·9936 | |
| IL-8 | 0·9985 | 0·9929 1·0041 | 0·5934 | |
| IL-10 | 1·0163 | 0·9769 1·0573 | 0·4234 | |
| TNF-α | 1·0115 | 0·9443 1·0834 | 0·7450 | |
| Lymphocyte | 1·2623 | 0·7412 2·1499 | 0·3911 | |
| Neutrophil | 1·0638 | 0·9467 1·1953 | 0·2986 | |
| PCT | 2·5333 | 0·7287 8·8067 | 0·1437 | |
| IL-2R/lymphocytes | 1·0013 | 1·0005 1·0021 | 0·0020 | |
| CRP | 1·0085 | 1·0008 1·0163 | 0·0300 | |
| Ferritin | 1·0006 | 1·0001 1·0010 | 0·0206 | |
| Huang, 2020 | All patients (n = 41) | All patients (n = 41) | No ICU care (n = 28) | ICU care (n = 13) |
| White blood cell count, ×109 L−1 | 6·2 (4·1–10·5) | 5·7 (3·1–7·6) | 11·3 (5·8–12·1) | |
| Neutrophil count, ×109 L−1 | 5·0 (3·3–8·9) | 4·4 (2·0–6·1) | 10·6 (5·0–11·8) | |
| Lymphocyte count, ×109 L−1 | 0·8 (0·6–1·1) | 1·0 (0·7–1·1) | 0·4 (0·2–0·8) | |
| Liu, 2020 | No ICU care (n = 28) | Mild Cases | Severe Cases | |
| IL-6 (pg/mL) | 5·7 (3·1–7·6) | 25 | 75 | |
| IL-10 (pg/mL) | 4·4 (2·0–6·1) | 3 | 4 | |
| IL-2 (pg/mL) | 1·0 (0·7–1·1) | 1.8 | 2.3 | |
| IL-4 (pg/mL) | 1.7 | 2 | ||
| TNF-α (pg/mL) | 2 | 2 | ||
| IFN-γ (pg/mL) | 2 | 2 | ||
| Wan, 2020 | Mild (mean [SD]) | Severe (mean [SD]) | ||
| CD4 | (451∙3 [23∙0]) | (263∙2 [28∙83]) | ||
| CD8 | (288∙6 [14∙23]) | (179 [23∙87]) | ||
| B cell | (166 [11∙98]) | (125∙3 [13∙49]) | ||
| NK cell | (147 [10∙36]) | (119∙6 [16∙500]) | ||
| CD4/ CD8 | (1∙671 [0∙059]) | (1∙509 [0∙170]) | ||
| IL-4 | (1∙69 [0∙070]) | (1∙83 [0∙185]) | ||
| IL-6 | (13∙41 [1∙84]) | (37∙77 [7∙801]) | ||
| IL-10 | (2∙464 [0∙085]) | (4∙59 [0∙378]) | ||
| IL-17 | (1∙095 [0∙0226]) | (1∙16 [0∙0571]) | ||
| TNF-α | (4∙077 [1∙588]) | (2∙948 [0∙443]) | ||
| IFN-γ | (5∙132 [0∙841]) | (6∙904 [1∙247]) | ||
| Zheng, 2020 | All Patients (n = 34). | IMV (n = 15) | NIV (n = 19) | |
| WBC (4–10/nL) | 8.9 (5.3, 14.3) | 6.2 (4.4, 13.5) | 9.3 (6.6, 16.0) | |
| C-reactive protein (0–8 mg/L) | 48 (27, 88) | 50 (39, 52) | 46 (27, 103) | |
| Interleukin-6 (0–7 pg/L) | 47 (24, 81) | 65 (38, 202) | 38 (12, 72) | |
| IL-10 (0.0–2.3 pg/mL) | 6.7 (4.4, 9.0) | 7.0 (5.2, 9.7) | 5.5 (3.1, 8.8) | |
| Neutrophil count ((×109 L−1) 2.0–7.0) | 7.8 (4.3, 13.2) | 5.7 (3.6, 12.8) | 8.0 (5.5, 14.8) | |
| Lymphocyte count ((×109 L−1) 0.8–4.0) | 0.6 (0.5, 0.9) | 0.5 (0.4, 0.8) | 0.6 (0.5, 0.9) |